Publication at First Faculty of Medicine |
2019
Abstract
Poly(ADP-ribose) polymerase inhibitors (PARP) represent the most modern approach to ovarian cancer treatment. This treatment is exclusive for individuals harbouring germline or somatic BRCA1 or BRCA2 gene mutations.
This case report presents a patient with recurrent ovarian cancer treated with oral PARP inhibitor olaparib as a part of third line treatment. Well tolerated treatment led to excellent long-term survival and quality of life.